CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL. Clin Cancer Res; 23(4); 873–5. ©2016 AACR.
See related article by Pikman et al., p. 1012
- Received November 22, 2016.
- Accepted November 23, 2016.
- ©2016 American Association for Cancer Research.